I call BULLSHIT. The game changer is that nothing has been done to solve anything to do with the neuronal cascade of death. Once again 'happy talk' pervades stroke instead of realism.
http://www.medpagetoday.com/Cardiology/Strokes/55483?xid=nl_mpt_DHE_2016-01-04&eun=g424561d0r
Endovascular therapy was a "game-changer" in stroke in 2015, leading specialists told MedPage Today.
Beginning in January with the MR CLEAN trial, through June with the publication of SWIFT PRIME and REVASCAT,
multiple studies demonstrated that thrombectomy outperformed tPA alone
in boosting 90-day functional independence by 13.5% to 31%.
An editorial in the New England Journal of Medicine called it a "sea change" and added, "It's about time."
In response to the question of what was the biggest clinical advance
of 2015, six of seven leading stroke specialists agreed: endovascular
therapy.
The response on stroke came from a survey of 55 neurologists, asking
their opinions on the biggest clinical advance in their subspecialty.
The "game-changers" selected in five major subspecialties were:
1. MS: Ocrelizumab results in ORATORIO and OPERA I and II
2. Stroke: Thrombectomy for acute ischemic stroke
3. Parkinson's disease: New therapies for delivering carbidopa/levodopa
4. Sleep: SERVE-HF trial showing adaptive servoventilation increased mortality
5. Alzheimer's disease: No single clinical advance stood out
Questions over optimal stroke therapy had persisted since three
trials in 2013 suggested endovascular therapy was no more effective than
intravenous tPA alone. But all that changed this year.
"Mechanical thrombectomy for acute ischemic stroke is a once-in-a-generation breakthrough in care," said Jeffrey L. Saver, MD, director, UCLA Comprehensive Stroke Center and first author of the SWIFT-PRIME trial.
"More patients will be going home free of disability after large ischemic strokes than ever before," said Pat Lyden, MD, chair of neurology and director of the Cedars-Sinai Stroke Center in Los Angeles.
And Joseph Broderick MD,
director of the University of Cincinnati Neuroscience Institute,
labeled it the "biggest change in acute stroke therapy since tPA
approval for stroke in 1996."
The breakthrough of thrombectomy came about, experts say, because of
several factors: improvement in technology of the stent receiver device
which can achieve more complete recanalization; improved workflow
efficiencies producing faster door-to-treatment times; and change in
neuroimaging criteria for identifying large vessel occlusions.
The positive results of these trials is now leading to new questions about ways to improve treatment.
In imaging, said Wayne Clark, MD,
director of the Oregon Health & Science University Stroke Center in
Portland, "Advances in imaging technology now allow us to identify
patient's that can still benefit from thrombectomy even if they are past
eight hours due to 'waking up' with their symptoms."
Marilyn Rymer, MD,
vice president for Neuroscience, University of Kansas Medical Center,
believes the field now faces a number of important questions about
imaging: "Can (we) select cases likely to have a good outcome with EVT
based on imaging criteria and potentially expand the number of eligible
cases well beyond the usual time window? What imaging criteria should be
used? Are imaging criteria the best way to select appropriate cases for
EVT?"
Also, access to endovascular therapy is currently a limiting factor.
It "needs to be given in advanced centers with clinical expertise and
the necessary acute and post-treatment support structure," said Larry B. Goldstein, MD,
Ruth L. Works professor and chair of neurology, University of Kentucky.
But these patients cannot be easily transported to the centers. "It
remains to be determined how best to integrate this approach into
overall systems of care on a regional and state-wide basis," he said.
Lyden says possible solutions are novel approaches for triage in the
field including "new paramedic tools; in-ambulance telemedicine; or even
the mobile stroke units that contain a CT scanner on the ambulance."
No comments:
Post a Comment